Enthusiasts say high-temperature sessions sharpen focus, improve health, and offer a chance to build contacts. It’s a far cry ...

Pulling the trigger on 555,937 shares, the value of the holding comes in at $6,421,000.Turning to the analyst community, Needham’s Chad Messer tells clients that he has high hopes ahead of the ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, varegacestat for desmoid tumors, is not an ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I ...

Messer, Jack, A. age 80 passed away on April 3rd, 2024, beloved husband of Nancy Messer, caring father of Chad (Shilpa) Messer and Douglas (Erica) Messer, dear brother of the late Frank (Barbara ...

Hundreds of kids in our area are losing their parents to drugs, creating a demand for foster homes that the system can't keep up with.

Super flyweight prospect Marisa Messer-Belenchia and undefeated featherweight prospect Tramaine Williams got special proclamations and former three-time light heavyweight world champion Chad Dawson ...

In line with Messer’s bullish stance, Nurix is a Strong Buy based on 5 unanimous Buys. The average Nurix price target of $48.80 implies upside potential of 114.9% from the current levels.

With the positive results, Sarepta Therapeutics will seek approval from the Food and Drug Administration later this year for a drug, to treat the Duchenne muscular dystrophy.

"We believe the timing of the deal reflects Amgen's confidence in the program," Needham's Chad Messer says of yesterday's strategic collaboration ...

“Sweat equity takes on a whole new meaning when you’re networking in a hot room,” says Chad Messer, a managing director at US ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab IMAB offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...